These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38449790)

  • 1. Gene expression in metastatic breast cancer-patterns in primary tumors and metastatic tissue with prognostic potential.
    Tutzauer J; Larsson AM; Aaltonen K; Bergenfelz C; Bendahl PO; Rydén L
    Front Mol Biosci; 2023; 10():1343979. PubMed ID: 38449790
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
    Lundgren C; Tutzauer J; Church SE; Stål O; Ekholm M; Forsare C; Nordenskjöld B; Fernö M; Bendahl PO; Rydén L
    Breast Cancer Res; 2023 Sep; 25(1):110. PubMed ID: 37773134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.
    Jørgensen CLT; Larsson AM; Forsare C; Aaltonen K; Jansson S; Bradshaw R; Bendahl PO; Rydén L
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
    Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
    Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
    Gunnarsdottir FB; Bendahl PO; Johansson A; Benfeitas R; Rydén L; Bergenfelz C; Larsson AM
    Breast Cancer Res; 2023 Mar; 25(1):29. PubMed ID: 36945037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
    Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.
    Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.
    Stefanovic S; Deutsch TM; Riethdorf S; Fischer C; Hartkopf A; Sinn P; Feisst M; Pantel K; Golatta M; Brucker SY; Sütterlin M; Schneeweiss A; Wallwiener M
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer.
    Wang X; Bi X; Huang Z; Huang J; Xia W; Shi W; Yuan Z
    Endocr Relat Cancer; 2020 Apr; 27(4):199-208. PubMed ID: 31958314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer.
    Morales S; Velasco A; Gasol A; Córdoba F; Vidal J; Serrate A; Valls J; Samame JC; Gisbert R; Moral D; Llombart-Cussac A; Salud A; Matias-Guiu X
    Cancer Treat Res Commun; 2018; 16():13-17. PubMed ID: 31298997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
    Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
    Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic heterogeneity predicts patient prognosis of HER2-positive metastatic breast cancer: A retrospective study based on SEER database.
    Wang Y; Liang Y; Ye F; Luo D; Jin Y; Li Y; Zhao W; Chen B; Wang L; Yang Q
    Cancer Med; 2023 Sep; 12(18):18597-18610. PubMed ID: 37605516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.
    Schettini F; Martínez-Sáez O; Falato C; De Santo I; Conte B; Garcia-Fructuoso I; Gomez-Bravo R; Seguí E; Chic N; Brasó-Maristany F; Paré L; Vidal M; Adamo B; Muñoz M; Pascual T; Ciruelos E; Perou CM; Carey LA; Prat A
    ESMO Open; 2023 Jun; 8(3):101214. PubMed ID: 37075698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
    Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
    Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M
    Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.